Skip to content

Efficacy of MySkin Patch for the Healing of Burn Wounds: a Randomised Controlled Trial

Efficacy of MySkin Patch for the Healing of Burn Wounds: a Randomised Controlled Trial

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01499264
Enrollment
120
Registered
2011-12-26
Start date
2012-01-31
Completion date
2014-10-31
Last updated
2014-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns, Burn Injury, Hydrogel Bandage, Occlusive Dressings

Keywords

MySkin patch

Brief summary

Evaluation of clinical efficacy of my skin (hydrogel and polyurethane film) plus best practice clinical care in subjects with burn injuries with particular regard to: 1) Wound healing (complete reepithelialization), 2) the patient's pain. In the context of the study will be collected secondary outcomes related to type of lesion and its clinical evolution through the analysis of the items in the scale of the PSST.

Interventions

Hydrogel and polyurethane film

Gauze and Patch

Sponsors

Artsana S.p.a.
CollaboratorINDUSTRY
Associazione Infermieristica per lo studio delle Lesioni Cutanee
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Presence of at least one injury burn covered by a dressing of 10x8 cm (80 cm2) * Injury treated with medication in use at the center * Patients assisted at the emergency care, or at the outpatient * Extension of the lesion less than 80 cm2 (including dressings in cm10x8cm) * Patient age greater than or equal to 18 years * Patients who have given consent to enrollment in the trial and the processing of personal data * Patient / lesion that has already been recruited in the study or who have previously passed a period of 10 days (washout) of no treatment according to the research protocol

Exclusion criteria

* A end-stage of disease * Suspected or known allergic diathesis to the product of medication * Subjects that do not give consent to data processing * Dry lesion with necrosis or eschar * Presence of both local and systemic infection or inflammation * Injuries that to the decision of the provider of care, needs a targeted local treatment other than as provided for in the Protocol * Patient / lesion that has already been previously recruited into the study, before a period of 10 days (washout) of suspension from the same research protocol * Patients who use alternative medicine treatments such as aloe

Design outcomes

Primary

MeasureTime frame
Wound healing and Significant reduction in pain1 month

Secondary

MeasureTime frame
Clinical evaluation of the lesion scores for each visit, the presence / absence of infection for each visit1 month

Countries

Italy

Contacts

Primary ContactAngela Peghetti
angela.peghetti@aosp.bo.it3401848409

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026